Equity Profile

EWTX

Edgewise Therapeutics, Inc.

Health CarePharmaceuticals$3.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market traction and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

EWTX Q2-2026 Earnings Preview

Context

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for rare diseases. Operating in the health care sector, it aims to address unmet medical needs, which is increasingly important as the demand for specialized therapies grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.24%

Avg Stock Reaction

-1.70%

Last Quarter Recap

In Q1-2026, Edgewise reported an EPS of -$0.46, which was better than the expected -$0.50, resulting in a positive surprise. However, the stock fell 3.81% the following day, indicating market disappointment despite the beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Edgewise's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors will be looking for any signs of revenue growth and improved EPS.

Bull Case

If Edgewise can demonstrate significant progress in its drug development pipeline or show strong demand for its therapies, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations for revenue or shows continued losses, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for Edgewise's pipeline products?

Revenue growth will be a critical indicator of the company's market performance and acceptance of its therapies.

Will the EPS continue to improve or will losses persist?

Continued improvement in EPS is essential for investor confidence and could influence stock performance significantly.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Edgewise's therapies to gain traction, as recent developments in the rare disease space suggest increased demand.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect more volatility than historical performance suggests.

Past earnings surprises have shown that even small beats can lead to negative stock reactions, indicating a potential disconnect between expectations and reality.

Key Risk

If the company reports a significant improvement in revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Edgewise can show tangible progress in its financial metrics amidst ongoing development challenges.

Bull Confirmed If

Demonstrating revenue growth of at least 10% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

If EPS does not improve and remains below -$0.46, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a move of approximately 4.5%, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±4.5% while EWTX has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.4%

Calls (3K)P/C Ratio: 0.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edgewise beats expectations, history suggests the stock could rise by around 2.5% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may experience minimal movement as investors reassess future growth prospects.

Miss

Should the company miss expectations, history indicates a potential drop of about 2% on the first day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of drug development in the pipeline.
2Details on partnerships or collaborations that could enhance market reach.
3Insights into market demand for Edgewise's therapies.
4Management's outlook on future earnings and revenue projections.
5Responses to questions about ongoing challenges in the rare disease market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market traction and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

EWTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.24%

Avg Stock Reaction

-1.70%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Edgewise can demonstrate significant progress in its drug development pipeline or show strong demand for its therapies, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations for revenue or shows continued losses, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for Edgewise's pipeline products?

Revenue growth will be a critical indicator of the company's market performance and acceptance of its therapies.

Will the EPS continue to improve or will losses persist?

Continued improvement in EPS is essential for investor confidence and could influence stock performance significantly.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Edgewise's therapies to gain traction, as recent developments in the rare disease space suggest increased demand.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect more volatility than historical performance suggests.

Past earnings surprises have shown that even small beats can lead to negative stock reactions, indicating a potential disconnect between expectations and reality.

Key Risk

If the company reports a significant improvement in revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Edgewise can show tangible progress in its financial metrics amidst ongoing development challenges.

Bull Confirmed If

Demonstrating revenue growth of at least 10% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

If EPS does not improve and remains below -$0.46, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a move of approximately 4.5%, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±4.5% while EWTX has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.4%

Calls (3K)P/C Ratio: 0.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edgewise beats expectations, history suggests the stock could rise by around 2.5% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may experience minimal movement as investors reassess future growth prospects.

Miss

Should the company miss expectations, history indicates a potential drop of about 2% on the first day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of drug development in the pipeline.
2Details on partnerships or collaborations that could enhance market reach.
3Insights into market demand for Edgewise's therapies.
4Management's outlook on future earnings and revenue projections.
5Responses to questions about ongoing challenges in the rare disease market.